TY - CHAP
T1 - Hetero-oligomerization and specificity changes of G protein-coupled purinergic receptors
T2 - Novel insight into diversification of signal transduction
AU - Suzuki, Tokiko
AU - Namba, Kazunori
AU - Mizuno, Natsumi
AU - Nakata, Hiroyasu
N1 - Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2013
Y1 - 2013
N2 - The formation of homo- and hetero-oligomers between various G protein-coupled receptors (GPCRs) has been demonstrated over the past decade. In most cases, GPCR heterodimerization increases the diversity of intracellular signaling. GPCR-type purinergic receptors (adenosine and P2Y receptors) are actively reported to form hetero-oligomers with each other, with GPCRs belonging to the same group (type 1, rhodopsin-like), and even with GPCRs from another group. This chapter describes common strategies to identify dimerization of purinergic receptors (coimmunoprecipitation, bioluminescence resonance energy transfer (BRET), and immunoelectron microscopy) and to assess the alteration of their pharmacology (ligand binding, intracellular cAMP, and intracellular Ca2 + assays). We have reported dimerization of purinergic receptors using these strategies in transfected human embryonic kidney 293T cells and native brain tissue. Our data suggest that homo- and hetero-oligomerization between purinergic receptors exert unique pharmacology in this receptor group. According to these discoveries, heterodimerization is likely to be employed for the "fine-tuning" of purinergic receptor signaling.
AB - The formation of homo- and hetero-oligomers between various G protein-coupled receptors (GPCRs) has been demonstrated over the past decade. In most cases, GPCR heterodimerization increases the diversity of intracellular signaling. GPCR-type purinergic receptors (adenosine and P2Y receptors) are actively reported to form hetero-oligomers with each other, with GPCRs belonging to the same group (type 1, rhodopsin-like), and even with GPCRs from another group. This chapter describes common strategies to identify dimerization of purinergic receptors (coimmunoprecipitation, bioluminescence resonance energy transfer (BRET), and immunoelectron microscopy) and to assess the alteration of their pharmacology (ligand binding, intracellular cAMP, and intracellular Ca2 + assays). We have reported dimerization of purinergic receptors using these strategies in transfected human embryonic kidney 293T cells and native brain tissue. Our data suggest that homo- and hetero-oligomerization between purinergic receptors exert unique pharmacology in this receptor group. According to these discoveries, heterodimerization is likely to be employed for the "fine-tuning" of purinergic receptor signaling.
KW - Bioluminescence resonance energy transfer
KW - Coimmunoprecipitation
KW - Electron microscopy
KW - G protein-coupled receptor
KW - HEK293T cells
KW - Hetero-oligomer
KW - Homo-oligomer
KW - Purinergic receptor
UR - http://www.scopus.com/inward/record.url?scp=84873019413&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84873019413&partnerID=8YFLogxK
U2 - 10.1016/B978-0-12-391862-8.00013-2
DO - 10.1016/B978-0-12-391862-8.00013-2
M3 - Chapter
C2 - 23351743
AN - SCOPUS:84873019413
SN - 9780123918628
T3 - Methods in Enzymology
SP - 239
EP - 257
BT - G Protein Coupled ReceptorsTrafficking and Oligomerization
PB - Academic Press Inc.
ER -